Parkinson's Disease Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with Parkinson's disease based on a specific set of recognised diagnostic criteria (called MDS-UPDRS, Groups 1 and 2).
- People whose Parkinson's medication dose has been stable for at least 4 weeks before the start of the study.
- People who are enrolled in a social security or equivalent healthcare coverage system.
- People who have given free, informed, and written consent to take part in the study.
- People who have had ongoing (chronic) pain lasting more than 3 months (Group 1 only).
- People who do not have chronic pain (Groups 2 and 3 only).
- People whose pain has been identified as originating from the central nervous system, determined using a specific published method (Group 1 only) (confirm with trial site).
- People who have rated their pain intensity at 4 or higher on a standard 0–10 pain scale during the past month (Group 1 only).
- People who have rated their pain intensity lower than 3 on a standard 0–10 pain scale during the past month (Groups 2 and 3 only).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have an atypical form of Parkinson's disease (Groups 1 and 2).
- People whose Parkinson's disease involves severe, disabling involuntary movements (dyskinesia) and/or severe tremor (Groups 1 and 2).
- People who have a medical reason they cannot have a brain MRI or PET scan — for example, a pacemaker, metal implants in the body, claustrophobia, or a deep brain stimulation device or apomorphine pump that cannot be switched off.
- People who have a history of a head injury that caused loss of consciousness for more than 30 minutes.
- People who do not agree to be told if something unexpected or abnormal is found during their MRI or psychological assessments.
- People who have significant cognitive (thinking and memory) difficulties, as measured by a standard screening test (a score below 24 on the MoCA test).
- People with severe depression, as measured by a standard questionnaire (a score above 29 on the BDI).
- People who are unable to stop taking opioid-based pain medications in the week before the imaging appointment — this includes a wide range of medications such as codeine-containing products, morphine, fentanyl, tramadol, oxycodone, buprenorphine, methadone, and others (confirm with trial site for the full list).
- People who are unable to stop any relevant treatment before study procedures (confirm with trial site).
- People currently taking certain pain-relieving medications (such as anti-inflammatory drugs, paracetamol/acetaminophen, certain antidepressants, or anti-epileptic medicines used for pain), unless that treatment has been at a stable dose for at least 4 weeks before the study and does not affect a specific brain chemical system involved in the research (confirm with trial site).
- People who currently have, or have previously had, a dependence on any addictive substance according to recognised diagnostic criteria — with the exception of tobacco.
- People who have used recreational drugs that affect the brain systems being studied in this trial (including cannabis, CBD, opiates, MDMA, or ecstasy) in the past 3 months, or who use these regularly.
- Women who are pregnant, in labour, or currently breastfeeding.
- People who are currently deprived of their liberty by a court or government authority.
- People who are currently receiving compulsory psychiatric care.
- People who are currently residing in a health or social care facility for reasons unrelated to research.
- People who are under a legal protection arrangement such as guardianship or curatorship.
- People who are currently taking part in another interventional research study that has an exclusion period which has not yet ended.
- People who have already reached the maximum amount of financial compensation permitted per year for participation in research studies.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Stéphane THOBOIS, PHD, Hospices Civils de Lyon
Phone: 04 72 35 70 58
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Where this trial is recruiting
Primary endpoints
Difference between non-displaceable binding potential of radiotracer in brain region involved in pain
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.